A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
Pharmacology, Toxicology and Pharmaceutical Science
2
3%
Engineering
2
3%
Other
2
3%
Unknown
18
30%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2026.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from Gynecologic Oncology
#1,869
of 4,956 outputs
Outputs of similar age
#34,005
of 95,784 outputs
Outputs of similar age from Gynecologic Oncology
#16
of 35 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,956 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 32nd percentile – i.e., 32% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 95,784 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
